• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MediWound Announces CEO Transition

    5/17/22 7:01:00 AM ET
    $CCTS
    $GMDA
    $MDWD
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCTS alert in real time by email

    Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30

    Will replace current CEO Sharon Malka, who will join the Board of Directors

    YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Ofer Gonen as Chief Executive Officer (CEO) of MediWound as of June 30, 2022, succeeding Sharon Malka, who will join the Company's Board of Directors. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, Ltd. ("CBI"), MediWound's largest shareholder, for the past 5 years.

    "As the Board and I considered how to best position MediWound for continued growth and long-term success, we determined now is the right time to transition to our next phase of leadership," said Stephen T. Wills, Chairman of the Board. "Ofer's expertise and capabilities align closely with our vision of growing MediWound into a global multi-asset significant contributor in the treatment of patients for burns and wound care. His extensive managerial experience in leading companies, global networking and deep understanding of MediWound's strengths and potential, position him uniquely to lead MediWound in its further development. On behalf of the entire Board, I want to thank Sharon for his dedicated years of service and express our gratitude and deep appreciation for his contributions to the Company's advancement and success."

    Mr. Ofer Gonen noted, "I am honored and excited to assume the role of MediWound's Chief Executive Officer. Thanks to the strong foundations built by Sharon and his team, as well as the experience and ongoing support of our Board of Directors, MediWound has tremendous potential to grow into a leading global biopharmaceutical company. I look forward to focusing my efforts to achieve the next phase of MediWound's success as we continue to advance our lead programs to expand patient access to our technologies, and capitalize on opportunities ahead to generate significant value for our shareholders."

    Sharon Malka, CEO of MediWound stated, "I have accomplished my goal as CEO of positioning the Company for long-term success and a strong future. The Company's pipeline portfolio is in a strong position for continued growth, including market expansion of our successful commercial product, a potential near-term launch in the U.S., and a promising best-in-class therapy for wound care. It has been an honor to lead this company and the entire team at MediWound and now I look forward to supporting Ofer in my new role as a member of the board of directors, and helping the company realize the tremendous opportunities that lie ahead."

    Ofer Gonen will assume the role of the Chief Executive Officer after serving as the CEO of Clal Biotechnology Industries Ltd. (TASE: CBI) and Cactus Acquisition Corp. 1 (NASDAQ:CCTS). He has more than 20 years of experience in managing life science investments and global business collaborations. Mr. Gonen serves as a board member of several publicly-traded biopharmaceutical technology companies, including, Gamida Cell (NASDAQ:GMDA), MediWound (NASDAQ:MDWD) and Cactus (NASDAQ:CCTS), as well as a managing partner at the Anatomy Medical Fund. Prior to joining CBI, he was the General Manager of Biomedical Investments Ltd., and the founder and Managing Partner at Arte Venture Group. Mr. Gonen is a strong business development professional, skilled in entrepreneurship, global strategic partnerships, IPOs, licensing deals, and M&A transactions. He holds a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction.

    About MediWound Ltd.

    MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care, and tissue repair.

    NexoBrid®, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

    EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications in several Phase 2 trials.

    MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

    Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.

    Cautionary Note Regarding Forward-Looking Statements

    MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "continues," "believe," "guidance," "outlook," "target," "future," "potential," "goals" and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions.



    Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the COVID-19 pandemic. For example, we are unable to predict how the pandemic will affect the overall healthcare infrastructure, including the ability to recruit patients, the ability to conduct the studies in medical sites and the pace with which governmental agencies, such as the FDA, will review and approve regulatory submissions. Additional government-imposed quarantines and requirements to "shelter at home" or other incremental mitigation efforts also may impact our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.



    These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 17, 2022, Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

    Contacts:Monique Kosse
    Boaz Gur-LavieManaging Director
    Chief Financial OfficerLifeSci Advisors
    MediWound Ltd.212-915-3820
    [email protected][email protected]


    Primary Logo

    Get the next $CCTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCTS
    $GMDA
    $MDWD

    CompanyDatePrice TargetRatingAnalyst
    MediWound Ltd.
    $MDWD
    5/2/2025$25.00Buy
    Alliance Global Partners
    MediWound Ltd.
    $MDWD
    2/28/2025$39.00Buy
    Craig Hallum
    MediWound Ltd.
    $MDWD
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    MediWound Ltd.
    $MDWD
    12/22/2022$11.00Buy
    Maxim Group
    MediWound Ltd.
    $MDWD
    7/18/2022$7.00Outperform
    Oppenheimer
    Gamida Cell Ltd.
    $GMDA
    11/16/2021$14.00 → $12.00Buy
    Needham
    Gamida Cell Ltd.
    $GMDA
    11/16/2021$17.00 → $15.00Outperform
    Oppenheimer
    Gamida Cell Ltd.
    $GMDA
    11/1/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $CCTS
    $GMDA
    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

      Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30

      4/28/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica

      3/19/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $GMDA
    $MDWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leblanc Jeff bought $50,000 worth of Class A ordinary shares (100,000 units at $0.50), increasing direct ownership by 286% to 135,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      8/1/24 4:06:03 PM ET
      $CCTS
      Blank Checks
      Finance
    • Director Ridgway Adam John bought $15,000 worth of Class A ordinary shares (30,000 units at $0.50), increasing direct ownership by 86% to 65,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      7/29/24 4:02:12 PM ET
      $CCTS
      Blank Checks
      Finance

    $CCTS
    $GMDA
    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cactus Acquisition Corp. 1 Limited

      SC 13G/A - Cactus Acquisition Corp. 1 Ltd (0001865861) (Subject)

      11/15/24 2:15:30 PM ET
      $CCTS
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      11/14/24 7:55:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cactus Acquisition Corp. 1 Limited

      SC 13G/A - Cactus Acquisition Corp. 1 Ltd (0001865861) (Subject)

      11/14/24 5:30:34 PM ET
      $CCTS
      Blank Checks
      Finance

    $CCTS
    $GMDA
    $MDWD
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $CCTS
    $GMDA
    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on MediWound with a new price target

      Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

      5/2/25 8:15:09 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on MediWound with a new price target

      Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

      2/28/25 7:39:12 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Maxim Group reiterated coverage on MediWound with a new price target

      Maxim Group reiterated coverage of MediWound with a rating of Buy and set a new price target of $30.00 from $25.00 previously

      7/16/24 8:08:28 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $GMDA
    $MDWD
    SEC Filings

    See more
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      4/7/25 4:04:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B3 filed by MediWound Ltd.

      424B3 - MediWound Ltd. (0001593984) (Filer)

      3/28/25 4:05:31 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by MediWound Ltd.

      EFFECT - MediWound Ltd. (0001593984) (Filer)

      3/28/25 12:15:23 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $GMDA
    $MDWD
    Financials

    Live finance-specific insights

    See more
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica

      3/19/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

      YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:  1-833-630-1956Israel: 1-80-921-2373International: 1-412-317-1837Webcast: Click HERE    To access the call, partici

      3/3/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $GMDA
    $MDWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leblanc Jeff bought $50,000 worth of Class A ordinary shares (100,000 units at $0.50), increasing direct ownership by 286% to 135,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      8/1/24 4:06:03 PM ET
      $CCTS
      Blank Checks
      Finance
    • Large owner Arwm Inc Pte. Ltd. sold $50,000 worth of Class A ordinary shares (100,000 units at $0.50), decreasing direct ownership by 5% to 1,854,999 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      8/1/24 4:05:09 PM ET
      $CCTS
      Blank Checks
      Finance
    • Director Ridgway Adam John bought $15,000 worth of Class A ordinary shares (30,000 units at $0.50), increasing direct ownership by 86% to 65,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      7/29/24 4:02:12 PM ET
      $CCTS
      Blank Checks
      Finance

    $CCTS
    $GMDA
    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

      8/16/24 4:36:54 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

      For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

      4/17/23 1:02:15 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/30/22 4:38:06 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care